论文部分内容阅读
目的探讨MG7在外周血与组织中检测的一致性及MG7与胃癌复发转移的关系。方法采用酶联免疫吸附剂测定(enzyme-linked immunosorbent assay,ELISA)法检测外周血中MG7的表达量,同时采用免疫组化的方法检测组织中MG7的表达水平,比较两种检测结果的一致性,同时对患者进行随访,探讨不同MG7表达水平与患者复发转移的关系。结果外周血中MG7的阳性检测率为80.9%,组织中MG7阳性检测率为79.4%,二者的阳性检出率无明显差别。比较两种检测方法检测结果一致性,发现二者没有统计学差异(P>0.05)。MG7高表达的胃癌患者的无病生存期明显低于MG7低表达组的患者(P=0.037)。结论 MG7在外周血与组织中检测结果具有较高的一致性,MG7可以作为判断胃癌预后的指标之一。
Objective To investigate the consistency of MG7 detection in peripheral blood and tissues and the relationship between MG7 and the recurrence and metastasis of gastric cancer. Methods The expression of MG7 in peripheral blood was measured by enzyme-linked immunosorbent assay (ELISA), and the expression of MG7 was detected by immunohistochemical method. The consistency of the two results was compared At the same time, the patients were followed up to explore the relationship between the expression of different MG7 and the recurrence and metastasis of patients. Results The positive detection rate of MG7 in peripheral blood was 80.9%, and the positive detection rate of MG7 in tissue was 79.4%. There was no significant difference between the two. The consistency of test results between the two methods was compared, and there was no significant difference between them (P> 0.05). The disease-free survival of gastric cancer patients with MG7 overexpression was significantly lower than those with MG7 low expression (P = 0.037). Conclusion The results of MG7 in peripheral blood and tissues showed high consistency. MG7 can be used as one of the indicators to judge the prognosis of gastric cancer.